Private Equity · Patent Diligence
Investors & Lenders · Portfolio Assessment
The Portfolio The Balance Sheet Couldn't See: $260 Million In Licensing Value
The Outcome
$45M Annually Across six priority licensing opportunities
$260M Over Five Years Estimated combined licensing value
01
The Situation
An investor had capital in a synthetic biology company built on precision fermentation - and a patent portfolio that appeared nowhere in the numbers. Was the IP a real asset that could generate revenue, support partnerships, or protect the investment on the downside? Or was it just a line item burning renewal fees?
For an investor, that's not an academic question. If the portfolio has commercial value, it changes the company's revenue picture, its partnership leverage, and the recovery math if things go sideways. If nobody quantifies it, it's worth exactly zero in every conversation that matters.
02
What We Did
Step 01
Segmented The Portfolio By Technology And Market
We built a full taxonomy of the portfolio, mapping what the company actually had exclusive rights to across every industry where the underlying science could be applied.
Step 02
Mapped The Competitive And Commercial Landscape
We assessed competitive overlap, identified potential infringement targets, and evaluated where the portfolio's coverage intersected with existing market demand - particularly the pull toward sustainable and bio-based products.
Step 03
Quantified The Opportunities
Rather than a generic “strong portfolio” verdict, we identified specific near-term commercialization paths across chemicals, consumer products, food and beverage, industrial biotech, specialty lubricants, adhesives, and polymers - and put numbers on the best of them.
Same question, different portfolio? Thirty minutes is enough to find out.
Book a Call03
What Happened
The analysis surfaced six priority licensing opportunities with an estimated combined value of approximately $45 million annually - more than $260 million over five years. A portfolio that had been invisible on the balance sheet became a concrete, prioritized revenue roadmap the investor and the company could act on.
Just as important: the investor now knew which opportunities aligned with existing industry demand, which targets to approach first, and what the portfolio contributed to the downside case - information that reframes every future financing and partnership conversation.
The Cost Of Waiting
Thirty Minutes Is Enough To Know
Most patent portfolios held by growth-stage companies have never been valued by anyone - not the board, not the lenders, not the founders. Every quarter that passes is a quarter of licensing revenue not pursued and negotiating leverage not used. Thirty minutes is enough to tell you whether the portfolio you’re invested in deserves the same look.
Book a Call No pitch, no deck · I read my own email
More Case Studies
Other Portfolios, Same Question
Operating Companies · Portfolio Valuation
The Offer On The Table Undervalued The Portfolio By Multiples
Read The Case Study
Operating Companies · Patent Mining
The Revenue Was Already In The Portfolio. Nobody Had Mined For It.
Read The Case Study
Operating Companies · Independent Assessment
Is The Patent Strategy Actually Working? A Public Company Finds Out.
Read The Case Study
Operating Companies · Litigation Finance